- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks
U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks
UPDATED May 29, 2023
U.S. Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
665 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| DRMADermata Therapeutics | US$1.62 | -25.0% | -87.0% | US$5.2m | US$4.00 | PB0.6x | E-3.2% | n/a | ||
| NTLAIntellia Therapeutics | US$38.98 | -10.3% | -15.5% | US$3.4b | US$89.74 | PS64.2x | E16.8% | n/a | ||
| ALVRAlloVir | US$3.89 | -9.3% | 0.5% | US$349.8m | US$21.75 | PB1.8x | E62.2% | n/a | ||
| PROKProKidney | US$10.98 | 5.3% | 10.9% | US$2.6b | US$15.20 | PE15.6x | E26.1% | n/a | ||
| QGENQiagen | US$46.07 | 0.3% | 0.3% | US$10.5b | US$54.25 | PE20.8x | E10.9% | n/a | ||
| RVMDRevolution Medicines | US$25.61 | -3.2% | 50.8% | US$2.7b | US$31.44 | PS78.2x | E10.0% | n/a | ||
| NRIXNurix Therapeutics | US$9.79 | -4.4% | -3.0% | US$464.5m | US$29.38 | PS11.1x | E15.4% | n/a | ||
| BNTXBioNTech | US$105.27 | -9.5% | -35.6% | US$25.4b | US$161.43 | PE3.8x | E-12.3% | n/a | ||
| SPRYARS Pharmaceuticals | US$7.37 | -12.3% | n/a | US$698.5m | US$17.00 | PS1037.9x | E48.4% | n/a | ||
| EXELExelixis | US$19.13 | -1.0% | 4.4% | US$6.2b | US$24.99 | PE40.5x | E29.0% | n/a | ||
| PCVXVaxcyte | US$48.97 | -3.0% | 104.1% | US$4.6b | US$66.29 | PB4.9x | E-1.9% | n/a | ||
| SAVACassava Sciences | US$23.57 | -6.9% | -23.0% | US$984.0m | US$124.00 | PB4.8x | E5.5% | n/a | ||
| PMCBPharmaCyte Biotech | US$3.15 | 1.0% | 37.0% | US$52.9m | n/a | PB0.7x | n/a | n/a | ||
| SQLSeqLL | US$0.51 | -9.6% | -29.2% | US$7.0m | US$1.50 | PS225.8x | E-22.6% | n/a | ||
| TSVT2seventy bio | US$11.98 | -0.2% | -3.4% | US$601.4m | US$28.17 | PS4.8x | E14.2% | n/a | ||
| AMPHAmphastar Pharmaceuticals | US$44.14 | 1.0% | 18.8% | US$2.1b | US$44.33 | PE22.9x | E10.4% | n/a | ||
| TRVITrevi Therapeutics | US$2.43 | 1.3% | 0.4% | US$146.0m | US$7.40 | PB1.4x | E-24.1% | n/a | ||
| APVOAptevo Therapeutics | US$1.65 | -8.8% | -64.0% | US$12.0m | US$14.50 | PE0.7x | E35.9% | n/a | ||
| NGMNGM Biopharmaceuticals | US$3.17 | -7.0% | -77.1% | US$261.1m | US$5.71 | PS7.1x | E4.4% | n/a | ||
| XCURExicure | US$0.85 | -4.2% | -78.8% | US$7.1m | n/a | PB0.5x | n/a | n/a | ||
| ATOSAtossa Therapeutics | US$0.87 | 3.8% | -10.5% | US$110.1m | US$4.63 | PB1x | E63.9% | n/a | ||
| ALPNAlpine Immune Sciences | US$9.90 | -5.8% | 6.5% | US$474.9m | US$15.00 | PS18.4x | E-22.0% | n/a | ||
| GRPHGraphite Bio | US$2.67 | -8.6% | 13.6% | US$155.1m | US$2.80 | PB0.6x | E-8.9% | n/a | ||
| ATXSAstria Therapeutics | US$10.93 | -16.9% | 195.4% | US$306.3m | US$24.43 | PB2.6x | E41.9% | n/a |